Italy’s Little-Known Early Access Program
Executive Summary
Italy’s early access system is mainly used for unapproved uses of authorized medicines, and is driven by clinicians, rather than companies.
You may also be interested in...
EU Avastin Court Ruling Deals Yet Another Blow To Novartis
In the latest in a string of knockbacks for both Novartis and Roche, the EU’s highest court has said that the Italian authorities are within their rights to reimburse Roche’s Avastin for wet AMD, even though it is not approved for that indication.
Regulatory Flexibilities Help Ease EU Amoxicillin Shortages
The European Medicines Agency says that the current shortage of antibiotics containing amoxicillin is not a “major event” and that efforts by EU and national regulators are helping to mitigate the situation.
UK Prepares For New International Regulatory Reliance Framework
From next year, more agencies will be involved in the UK’s regulatory reliance procedure for new drug approvals, which was first introduced in 2021 to allay fears of post-Brexit delays to UK applications. The pharmaceutical industry said it looked forward to working with the regulator on the new framework.